AV

AvenCell

5 known investors

avencell.com ↗

AvenCell develops next-generation CAR-T cell immunotherapies for hard-to-treat cancers, using proprietary Universal Switchable CAR and allogeneic platforms with an on/off mechanism combining universal effector cells and soluble Targeting Modules. The therapies aim to improve controllability and safety over current T cell-based immunotherapies.

Investors · 5

EI

Eight Roads VenturesBangalore · $5M – $30M

F-

F-Prime Capital PartnersCambridge · $3M – $10M

NO

Novo HoldingsCopenhagen · $1.1M – $54M

NY

NYBC VenturesNew York

NY

NYBC Venturesreported